SecBot SecBot
SECBOTREPLAY Home › Report › BCAX

BCAX · Bicara Therapeutics reported Q2 2026 results with a net loss of $0.82…

Bicara Therapeutics Inc. · PRESS-RELEASE filed Aug 11, 2026 at 07:30 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Aug 11, 2026 at 07:30 ET

Bicara Therapeutics reported Q2 2026 results with a net loss of $0.82 per share, slightly better than the $0.83 consensus estimate. The filing is dominated by a major leadership transition, with CEO Claire Mazumdar stepping down effective January 2027 and President/COO Ryan Cohlhepp taking over, alongside several other C-suite changes. The company's pivotal FORTIFI-HN01 trial remains on track for an interim analysis in mid-2027, and cash runway extends into H1 2029, but the leadership overhaul introduces execution risk at a critical juncture.

  • Net loss of $0.82 per share vs $0.83 consensus (0.7% beat)
  • CEO Claire Mazumdar to step down Jan 2027, succeeded by COO Ryan Cohlhepp
  • CFO Ivan Hyep replaced by Jenn Larson effective Aug 12, 2026
  • FORTIFI-HN01 pivotal trial substantially enrolled by year-end, interim analysis mid-2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access